Publications by authors named "C E Foucar"
Article Synopsis
- The t(1;19) chromosomal translocation is linked to a specific subtype of B-acute lymphoblastic leukemia (B-ALL), traditionally seen as a negative indicator in children, but possibly having a different impact on adults, particularly those treated with pediatric regimens.
- A case study of a 70-year-old woman with this translocation reveals the complexity of B-ALL, as she initially achieved remission but later relapsed and faced poor outcomes despite various treatment efforts.
- The findings point to the diverse nature of B-ALL, suggesting that even patients with favorable genetic markers may not respond well to standard treatments or targeted therapies.
Article Synopsis
- CBF-AML is classified as a favorable risk leukemia and often treated with intensive chemotherapy (IC) that may include the drug gemtuzumab ozogamicin (GO).
- A study of 200 patients showed that adding GO to IC did not improve overall survival (OS) or event-free survival (EFS) compared to IC alone, with 3-year EFS rates of 50% and 47%, respectively.
- In contrast, patients receiving IC with KIT inhibitors (like dasatinib or midostaurin) had a significantly better 3-year EFS of 85%, highlighting the effectiveness of KIT inhibitors over the addition of GO.
Aplastic anemia (AA) is a rare bone marrow failure disorder that is treated with either allogeneic stem cell transplant or immunosuppressive therapy (IST) consisting of antithymocyte globulin (ATG), cyclosporine (CSA), and eltrombopag. While outcomes are favorable in younger patients, older patients (>60) have significantly worse long-term survival. The dose of ATG is often reduced in older patients and those with multiple comorbidities given concerns for tolerability.
View Article and Find Full Text PDFPhiladelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with a worse prognosis compared to Ph negative ALL. Tyrosine kinase inhibitor (TKI) therapy has led to an improvement in response rates and survival, thus becoming a critical component of therapy. We performed a retrospective cohort study of Ph+ ALL patients treated at the University of Michigan who received TKI therapy pre- and post-allogeneic hematopoietic stem cell transplant (HSCT) from April 2007 to November 2019.
View Article and Find Full Text PDFIn recent years, an explosion of novel agents has shifted the treatment paradigm for patients with acute myeloid leukemia. The optimal place in therapy for many of these novel agents remains unknown due to limited guidance from national guidelines and the way these agents were studied prior to entering the market. A critical evaluation of the literature and incorporation of oncology stewardship principles can be helpful in determining an optimal place for these agents while being mindful of the overall cost that is associated with therapies.
View Article and Find Full Text PDF